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Psychiatric disorders such as schizophrenia, bipolar disorder,
major depressive disorder, attention-deficit/hyperactivity
disorder and autism spectrum disorder are common and
result in significantmorbidity andmortality. Although
currently classified into distinct disorder categories, they
show clinical overlap and familial co-aggregation, and share
genetic risk factors. Recent advances in psychiatric
genomics have provided insight into the potential
mechanisms underlying the overlap between these
disorders, implicating genes involved in neurodevelopment,
synaptic plasticity, learning andmemory. Furthermore,
evidence from copy number variant, exome sequencing
and genome-wide association studies supports a gradient
of neurodevelopmental psychopathology indexed by
mutational load ormutational severity, and cognitive
impairment. These findings have important implications for
psychiatric research, highlighting the need for new
approaches to stratifying patients for research. They also
point theway for work aiming to advance our
understanding of the pathways from genotype to clinical
phenotype, whichwill be required in order to inform new
classification systems and to develop novel therapeutic
strategies.patients are diagnosed with more than one disorder. Co-The overlap between psychiatric disorders:
challenges to current nosology
Psychiatric disorders are common in the population [1] and
result in considerable morbidity and mortality [2]. Over the
decades, psychiatric classification systems such as the
Diagnostic and Statistical Manual of Mental Disorders
(DSM) [3] and the International Classification of Diseases
(ICD) [4] have been developed and revised in order to* Correspondence: owenmj@cardiff.ac.uk
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reproduction in any medium, provided the orimprove the reliability of clinical diagnosis, inform treatment
strategies and guide research. However, in the absence of
objective diagnostic tests for psychiatric disorders, such
classifications are largely descriptive and syndromic, describ-
ing constellations of symptoms and signs that tend to occur
together. These classification systems thus define psychiatric
disorders such as schizophrenia, bipolar disorder, major
depressive disorder, attention-deficit/hyperactivity disorder
(ADHD) and autism spectrum disorder (ASD) categorically,
according to the quality and quantity of symptoms and signs
present. Treatment guidelines have been developed on the
basis of these diagnostic categories. For example, schizo-
phrenia is treated with antipsychotics, bipolar disorder
with mood stabilizers and antipsychotics, major depres-
sion with antidepressants and ADHD with psychostimu-
lants (Table 1).
However, it is widely acknowledged that there is sub-
stantial heterogeneity within diagnostic categories and
that the boundary between disorder and ‘normality’ is
not always clear. Furthermore, many symptoms and
signs overlap between disorder categories and patients
often present with features of more than one disorder.
In some cases, this overlap has been dealt with by recog-
nizing diagnostic ‘interforms’ such as schizoaffective dis-
order [11], or by recognizing ‘comorbidity’, whereby
morbidity is often obscured in research by the use of
diagnostic hierarchies or exclusions. For example, until
the publication of the most recent edition of the DSM
(DSM-5), it was not possible to co-diagnose ASD and
ADHD. However, it is estimated that 30 to 80% of children
with ASD also have ADHD [12,13]. Given these diagnostic
issues, it is perhaps unsurprising that neuroscientific ad-
vances have thus far failed to identify specific risk factors
or biomarkers that map onto disorder categories on a one-
to-one basis. Indeed, there is accumulating evidence sup-
porting biological overlap between disorders, fuelling in-
vestigation into the underlying mechanisms.entral Ltd. The licensee has exclusive rights to distribute this article, in any
ion. After this time, the article is available under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical features, age of onset, lifetime prevalence and pharmacological management of major mental
disorders










Cognitive impairment 7 to 12 5 [5] Psychostimulants
(for example, methylphenidate)
ASD Deficits in social communication
and social interaction




<3 1 to 2 [6-8] No recommended drug
treatment






Lack of emotional reactivity
Cognitive impairment
Discrete episodes of elevated,
irritable or agitated mood
Episodes of low mood




Discrete episodes of elevated,
irritable or agitated mood
Episodes of low mood
Hallucinations
Delusions







Loss of interest or pleasure
Lack of energy
Psychosis 20 to 45 12.5 [10] Antidepressants
(for example, citalopram)
ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorder.
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paradigm shift in psychiatric research. These studies pro-
vide converging evidence across a number of different
levels, supporting the hypothesis that genetic risk factors
are shared between disorders and challenging the validity
of the classification systems currently used in research
and clinical practice. The evidence suggests that investi-
gating pathways common across disorders may help us to
understand the etiology of psychiatric illness. This could
revolutionize our approach to the diagnosis and treatment
of these complex disorders. Here, we review recent evi-
dence from family and genomic studies, which support an
overlapping and complex genetic architecture for psychi-
atric disorders and provide new avenues for further inves-
tigation of underlying mechanisms.
Family studies
Twin, family and adoption studies have provided herit-
ability estimates for the major psychiatric disorders,
highlighting an important role for genetic factors in the
etiology of mental disorders [11,14-18].
In the late 19th century, Emil Kraepelin, a prominent
German psychiatrist, distinguished between ‘dementia
praecox’ (later termed schizophrenia) and manic-
depressive psychosis (later termed bipolar disorder) as
the two most common functional psychoses. Many fam-
ily studies seemed to support this so-called ‘Kraepelinian
dichotomy’, finding no familial relationship between
schizophrenia and bipolar disorder, suggesting that these
disorders ‘breed true’ [19-22]. These studies typically
used hierarchical main-lifetime diagnoses - the predom-
inant diagnosis an individual is given - in whichschizophrenia was ranked higher than bipolar disorder.
Therefore, patients who had several manic or depressive
episodes in the past but who mostly had symptoms of
schizophrenia later in the course of their illness would
be given a main-lifetime diagnosis of schizophrenia.
However, when non-hierarchical approaches were used,
familial co-aggregation between schizophrenia, bipolar
disorder [23] and schizoaffective disorder [24] was ob-
served. This overlap in familial risk was confirmed in a
meta-analysis of family studies of schizophrenia and bi-
polar disorder [25]. Recent large-scale population studies
in Swedish cohorts have expanded on this, showing that
a family history of schizophrenia, mood disorders, ASD
and ADHD is associated with cross-disorder risk [26,27].
The overlap between major depressive disorder and
other mental disorders is less clear. A meta-analysis of
family high-risk studies recently compared offspring of
parents with schizophrenia, bipolar disorder and major
depressive disorder [28]. The study showed that off-
spring of adults with schizophrenia, bipolar disorder or
major depressive disorder had a 32% probability of de-
veloping one of these disorders themselves by adulthood
and that risks to offspring were not limited to their par-
ent’s index disorder. For example, offspring of patients
with schizophrenia or bipolar disorder had an increased
risk of schizophrenia, bipolar disorder and major depres-
sive disorder. However, although the relative risk of
schizophrenia and bipolar disorder was also elevated in
offspring of parents with depression, this finding did not
reach statistical significance.
Vandeleur and colleagues [29] recently studied families
with mood disorders (schizoaffective disorder, bipolar
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egorical (disorder-based) and dimensional (symptom-
based) approaches. Interestingly, the authors found that
psychotic, manic and depressive symptoms were trans-
mitted independently, suggesting that studying familial
transmission of symptom dimensions may help to dis-
sect clinical phenotypes in order to better understand
the differential effects of genetic and environmental risk
factors.
It has long been known that schizophrenia is associ-
ated with cognitive impairment and that this often pre-
dates the onset of psychotic symptoms [30]. Family
studies show that the offspring of parents with schizo-
phrenia have worse cognitive function than the offspring
of unaffected parents [31], and that cognitive impair-
ment is associated with familial risk of schizophrenia
[32]. Applying genetic modeling to a combined family
and twin sample, Toulopoulou and colleagues [33]
showed that a large proportion of the phenotypic corre-
lations between schizophrenia and cognition are due to
shared genetic effects.
Taken together, the evidence from family studies sug-
gests that psychiatric disorders may be co-inherited but
also suggests that independent genetic and environmen-
tal risk factors are likely to be important in determining
the ultimate clinical phenotype.
Genomic studies
The epidemiological studies discussed above used the
genetic relationships between individuals to study the
co-inheritance of psychiatric disorders. Advances in gen-
omic technology, including array-based genome-wide as-
sociation studies (GWAS), and exome-sequencing
techniques, have allowed the potential genetic mecha-
nisms underlying the overlap between psychiatric disor-
ders to be investigated more directly. Like other
complex diseases such as hypertension and diabetes,
psychiatric disorders are not inherited in a Mendelian
fashion but have a complex genetic architecture involv-
ing a spectrum of mutations from small DNA sequence
variations to large chromosomal rearrangements. Not
only do these mutations vary in their size, they also vary
in their frequency and associated effect sizes. Below, we
discuss recent evidence for overlap in genetic risk factors
from GWAS of single nucleotide polymorphisms (SNPs),
studies of copy number variants (CNVs) and exome-
sequencing studies of single nucleotide variants (SNVs),
insertions and deletions (indels).
Single nucleotide polymorphisms
The introduction of genome-wide association platforms
has enabled researchers to study large samples of pa-
tients and controls to identify common variants (minor
allele frequency >0.01) with cross-disorder associations.The markers used in these studies are SNPs: points in
the DNA sequence where the nucleotide base varies in
the population. In a recent paper published by the
Cross-Disorder Group of the Psychiatric Genomics Con-
sortium (PGC), four SNPs were identified as being sig-
nificantly associated with the five psychiatric disorders
studied: schizophrenia, bipolar disorder, major depres-
sive disorder, ASD and ADHD [34]. Two of the SNPs
were located in genes encoding L-type voltage-gated cal-
cium channel subunits (CACNA1C and CACNB2). CAC-
NA1C has previously been reported as having genome-
wide significant associations with schizophrenia, bipolar
disorder and major depressive disorder [35-38], and
therefore there is strong evidence implicating calcium
channel signaling in the pathophysiology of mental dis-
orders. Other loci with cross-disorder associations in-
clude ANK3 [36,37], ZNF804A [39,40] and NCAN
[41,42], all of which have been reported in GWAS of
schizophrenia and bipolar disorder.
To date, GWAS of common SNPs have shown that in-
dividual SNPs have modest effect sizes (typical odds ratio
<1.2). It is therefore hypothesized that many common
SNPs act together to influence risk of psychiatric disor-
ders. Schizophrenia GWAS data support a polygenic basis
for the disorder and estimate that common SNPs explain
approximately one-third of the total variation in liability
to schizophrenia [43,44]. These data also show that gen-
etic liability is substantially shared with bipolar disorder
[43]. Polygenic score analysis of common variants has pro-
vided further evidence for shared genetic risk across disor-
ders. This approach uses a set of the top risk-associated
alleles from a case-control ‘discovery’ GWAS sample to
generate an aggregate score that can be used to test for
differences between cases and controls in an independent
‘target’ sample. Scores are assigned to each individual
based on the number of risk alleles they carry, weighted
by the effect size for each variant. These scores are
weighted by the effect size for each variant. Using this ap-
proach, it has been shown that alleles that are overrepre-
sented in schizophrenia cases are also overrepresented in
cases of bipolar disorder [43] and ADHD [45]. However,
schizophrenia alleles were not found to be overrepre-
sented in an ASD cohort [46]. Aggregate polygenic risk
scores in the PGC sample also showed cross-disorder ef-
fects, which were strongest for adult-onset disorders [34].
Furthermore, polygenic risk scores have been used to in-
vestigate the association between schizophrenia and cog-
nitive impairment. The Cognitive Genomics Consortium
reported that schizophrenia polygenic risk scores were
correlated with cognitive ability: higher ‘schizophrenia
load’ being associated with lower cognitive ability. The au-
thors also calculated cognitive polygenic scores and found
that patients with schizophrenia had more alleles associ-
ated with poor cognitive performance and fewer alleles
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[47]. In another study, schizophrenia polygenic risk score
was associated with lower cognitive ability at age 70 years
and with greater cognitive decline between childhood and
old age [48]. However, another recent study failed to find
an association between polygenic risk for schizophrenia
and IQ variation in either schizophrenia cases or controls
[49].
An alternative method for investigating the SNP-based
genetic overlap between disorders is to use a method
known as genome complex trait analysis (GCTA) [50] to
calculate SNP-based genetic correlations. This method
estimates the variance explained by all SNPs for a com-
plex trait rather than testing the association of any par-
ticular SNP to the trait. It assumes an additive model
and therefore does not account for gene-gene interac-
tions. Using this method, it has been estimated that
common variants contribute between 17 and 29% to the
variation in liability to mental disorders [51]. High cor-
relation was found between schizophrenia and bipolar
disorder; moderate correlation between major depressive
disorder and schizophrenia, major depressive disorder
and bipolar disorder, and major depressive disorder and
ADHD; and a small but significant correlation between
schizophrenia and ASD. Interestingly, no correlations
were found between other pairs of disorders, including
ASD and ADHD, bipolar disorder and ADHD, or schizo-
phrenia and ADHD. This was unexpected given the con-
siderable phenotypic overlap between these disorders
and data from family, twin and linkage studies, which
suggest shared genetic risk factors [27,52-55]. However,
when compared with adult-onset disorders, ADHD and
ASD cohort sizes were relatively small in this study and
therefore it may have been underpowered to detect
SNP-based correlations between these disorders. Fur-
thermore, there is increasing evidence for the role of
rare genetic variants such as CNVs in neurodevelopmen-
tal disorders and it is possible that these play a more sig-
nificant role in the overlap of ADHD and ASD than
common SNPs, although further studies of larger sam-
ples will be needed in order to adequately address this.
Copy number variants
Despite the high heritability of mental disorders reported
in family studies, GWAS findings to date suggest that
common variants only explain a relatively small propor-
tion (about a third) of the genetic variation in liability to
psychiatric illness [56]. Furthermore, the lack of SNP-
based genetic correlation between disorders such as
ADHD and ASD suggests a role for other types of variant
in the genetic architecture of mental disorders. There is
increasing evidence that rare structural variants (those
present in <1% of the population), such as CNVs, may also
be important. Owing to their low frequency in thepopulation, these variants are unlikely to be tagged by
common SNPs and therefore bring independent informa-
tion about the genetic etiology of psychiatric disorders.
Several studies have clearly demonstrated enrichment
for rare CNVs in psychiatric and developmental disorders.
For example, it has been shown that CNV burden is
higher in patients with schizophrenia [57-59], ADHD
[60,61], ASD [62], intellectual disability (ID) and develop-
mental delay [63] than in healthy controls. Furthermore,
CNV load and the ratio of de novo to inherited CNVs cor-
relate with the severity of developmental disability [63].
The role of CNVs in mood disorders is less clear. Sev-
eral studies have shown that patients with bipolar dis-
order have a low burden of rare CNVs [64-66]. However,
singleton deletions and de novo CNVs have been found
to occur at a higher rate in bipolar disorder cases than
in controls, particularly in early onset cases [67,68]. The
only genome-wide study of CNVs in major depressive
disorder found that deletions >100 kilobases (kb) in size
were significantly enriched in patients with recurrent de-
pression but that such CNVs explained only 0.87% of
the variance between cases and controls [69].
Microdeletions and duplications conferring risk of
schizophrenia have been reported at a number of chromo-
somal locations (Table 2) affecting genes involved in nu-
merous processes such as synaptic signaling, neuronal
migration, neurotransmitter metabolism and myelination.
These CNVs show incomplete penetrance and have pleio-
tropic effects, resulting in variable clinical phenotypes. ID,
ASD, ADHD, and mood and anxiety disorders commonly
occur, as do epilepsy, congenital malformations, facial dys-
morphology and developmental delay. Furthermore, ‘con-
trol’ carriers of CNVs (that is, those without a diagnosis of
a psychotic illness, ASD, ID or developmental delay) at a
number of known schizophrenia risk loci, including chro-
mosomes 15q11.2 and 16p11.2, have been shown to have
cognitive impairment, the severity of which is intermedi-
ate between that observed in patients with schizophrenia
and population controls [70].
Recent evidence suggests that CNVs may not only in-
crease risk of psychiatric disorders, they may also exert
protective effects. The 22q11.2 deletion is the strongest
known genetic risk factor for schizophrenia. Recently,
Rees and co-workers [110] found that the reciprocal du-
plication is less common in patients with schizophrenia
than in controls. This implies that studying CNVs may
also help us to understand mechanisms underlying re-
silience to mental disorders.
Single nucleotide variants and indels
GWAS and array-based techniques have enabled the de-
tection of small common (>1%) and large rare (<1%) mu-
tations. The development of exome-sequencing platforms
has enabled the identification of small rare coding
Table 2 Copy number variants associated with schizophrenia, their penetrance for schizophrenia, and associations
with other psychiatric disorders and intellectual disability
Locus Copy number change Penetrance Associations References
1q21.1 Deletion/duplication 5.2/2.9 ID, ASD, ADHD [57,58,71-75]
2p16.3 (NRXN1) Deletion 6.4 ID, ASD [57,58,74,76-81]
3q29 Deletion 18.0 ID, ASD [73-75,82]
7q11.2 Duplication 6.0 ID, ASD, ADHD, anxiety disorders [73,74,83-86]
15q11.2 Deletion 2.0 ID, ASD, ADHD, OCD [72-74,81,87-89]
15q11-13 Duplication 4.2 ID, ASD [73,74,90-92]
15q13.3 Deletion 4.7 ID, ASD, ADHD [57,72-75,93-96]
16p11.2 Deletion/duplication 2.6/8.0 ID, ASD, ADHD, mood disorders, anxiety disorders [62,73,74,91,97-102]
16p13.11 Duplication 2.2 ID, ASD, ADHD [61,73,74,81,103,104]
17q12 Deletion 4.0 ID, ASD [73,74,105]
22q11.2 Deletion 12 ID, ASD, ADHD, mood disorders, anxiety disorders [57,73,74,106-109]
ASD, autism spectrum disorder; ADHD, attention-deficit/hyperactivity disorder; ID, intellectual disability; OCD, obsessive-compulsive disorder.
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GWAS or array-based techniques. Using samples of trios
(both parents and one child) and quads (both parents with
two children), de novo gene-disrupting SNVs and indels
have been found to occur at higher rates in probands with
ASD [111-114] and ID [115,116], being present in up to
14% of ASD cases [113,114] and up to 55% of ID cases
[115] in the sampled cohorts. Furthermore, mutation rates
were found to correlate with increasing paternal [111-113]
and maternal [111,112] age, which is in line with epi-
demiological evidence for the positive correlation between
parental age and rates of disorders in offspring [117-120].
The first exome-sequencing studies in schizophrenia
found higher than expected rates of non-synonymous de
novo mutations in small samples of patients [121,122].
Two recent and much larger studies [123,124] did not
observe an increased rate of either non-synonymous or
loss of function de novo or inherited mutations in
schizophrenia. However, enrichment of loss of function
de novo mutations did occur in schizophrenia cases
likely to have the greatest intellectual impairment
(lowest scholastic attainment), although these did not in-
clude cases with diagnoses of severe intellectual impair-
ment. Moreover, genes with de novo mutations in
schizophrenia overlapped with those affected by de novo
mutations in ASD and ID but not in controls, with loss
of function mutations enriched even in the very small
subset of genes (N = 7) with recurrent loss of function de
novo mutations in ASD or ID [123]. These findings
therefore demonstrate shared genetic overlap between
schizophrenia, ASD and ID at the resolution not just of
loci or even of individual genes, but also at the level of
mutations with similar functional (loss of function)
impacts. The authors also observed that the genes hit by
de novo mutations and the mutation sites themselves
showed the highest degree of evolutionary conservation(a proxy measure of functional importance) in ID, then in
ASD, with least conservation seen in schizophrenia. These
findings suggest that highly disruptive mutations play a
relatively small role in schizophrenia, and also that the dis-
orders differ by severity of functional impairment.
Potential biological mechanisms for shared
genetic risk
Recently, evidence for the convergence of genetic find-
ings onto a coherent set of biological processes in psy-
chiatric disorders has been accumulating. Results from
GWAS [34,44], CNV [83,125] and sequencing studies
[114,123,124] point to highly functionally related sets of
post-synaptic proteins involved in neurodevelopmental
processes, synaptic plasticity, learning and memory.
These include L-type calcium channels, post-synaptic
scaffolding proteins involved in NMDA (N-methyl-D-as-
partate) signal transduction, proteins that interact with
ARC (activity-regulated cytoskeleton-associated protein),
referred to as the ARC complex [83], and brain-
expressed genes that are repressed by fragile X mental
retardation protein (FMRP) [123,126].
These findings are notable for their consistency across
several studies using different designs, and for their con-
vergence onto a set of biological processes involved in the
regulation of synaptic plasticity, particularly at glutamater-
gic synapses. Although there appears to be a concentration
on post-synaptic mechanisms, some implicated genes, in-
cluding the L-type calcium channels and neurexin 1 (an
associated CNV locus [127]) also exert effects on plasticity
pre-synaptically. Furthermore, these synaptic genes have
been implicated in cognition [128] as well as in a range of
psychiatric disorders, including schizophrenia, bipolar dis-
order, ASD and ID. However, the degree to which the as-
sociated pathways cross current diagnostic boundaries
remains to be fully established. It is highly unlikely that
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plicated in these disorders, but the identification of at least
one system involved in risk for schizophrenia and related
disorders paves the way for more detailed mechanistic
studies and potentially for stratified and novel therapeutic
approaches.
Convergent support for glutamatergic synaptic pro-
cesses is encouraging, but as already mentioned, it is
likely that other processes are involved. There is a highly
convincing body of evidence implicating dopaminergic
dysfunction in the genesis of psychotic symptoms, which
occur commonly in schizophrenia and bipolar disorder
but that also occur in other neurodevelopmental disor-
ders [129]. Indeed, the mechanism of action of anti-
psychotic drugs is understood to largely depend upon
the blockade of dopamine D2 receptors. Understanding
the relationship between glutamatergic dysfunction,
which is closely related to cognitive impairment, and
dopamine abnormalities is likely to be a fruitful ap-
proach to understanding how psychosis arises in schizo-
phrenia and related disorders.
It seems probable that genetic disruption of the synaptic
processes implicated to date will have widespread impacts
on brain function and impair information processing
within local, regional and even whole-brain networks - for
example, by affecting excitatory-inhibitory balance and/or
synaptic plasticity. Therefore, it is not surprising that mu-
tations in genes involved in these processes affect cogni-
tive function irrespective of the presence of comorbid
psychopathology [48,70].
A spectrum of neurodevelopmental causality has pre-
viously been proposed to underlie the overlap between
psychiatric disorders [130,131]. This proposed model
suggests that psychiatric disorders and ID lie on a gradi-
ent of severity, with ID at one extreme and mood disor-
ders at the other. Recent genomic evidence supports
such a model and extends it to include a gradient of mu-
tational severity or mutational load as well as cognitive
impairment (Figure 1). Under such a model, genetic fac-
tors (such as the nature, quantity, size and location of
deleterious genetic variants) and environmental factors
leading to early brain insult act together to alter neuro-
developmental trajectories: the timing, severity, anatom-
ical location and extent of the deviation from ‘normality’
determining the ultimate clinical phenotype. Further in-
vestigation, integrating genetic findings with cellular, ani-
mal, clinical and neuroimaging research, will shed more
light on whether such a model is plausible.
Implications for clinical diagnosis, management
and research
Advances in our understanding of the genetic architec-
ture of psychiatric disorders support the long-standing
clinical observation of overlap in the symptoms andsigns of these disorders, as well as the non-specificity of
many environmental risk factors [131]. However, we are
still some way off having sufficient new insights from
genetics and neuroscience to replace current diagnostic
approaches in the clinic. It is too early to say how
advances in neuroscience and genetics will affect classifi-
cation and diagnosis. Although current diagnostic
categories are likely to remain clinically useful where
they can best inform management and prognosis, these
categories will require modification as further research
indicates closer relationships of specific phenotypes and
endophenotypes to mechanisms, and will probably need
to include both dimensional (symptom-based) and
categorical (syndrome-based) components.
What is clear, however, is that research into etiology
and pathogenesis does require a radical overhaul in how
we diagnose psychiatric illness, moving from categorical,
hierarchical diagnoses based on consensus opinion to-
wards a more dimensional approach informed by ad-
vances in our understanding of brain mechanisms.
Indeed, such an effort is currently underway by the Re-
search Domain Criteria (RDoC) project [132,133]. This
project aims to provide the data required to build a new
classification system based on underlying biology. While
such a step is clearly needed, it will take a decade or
more for enough evidence to be accumulated to develop
a system that is suitable for clinical practice. However,
an immediate implication of recent genetic findings and
the RDoC project is the need to study patients who fall
into the ‘gray area’ between disorder categories [134] or
who have ‘subthreshold’ symptoms.
Pediatricians and clinical geneticists are increasingly
using genetic testing for patients referred with congeni-
tal malformations, facial dysmorphology, developmental
delay, ID and ASD [135,136]. So far, genetic testing has
not been widely adopted in psychiatry (see [137] for an
overview of some of the ethical issues involved in gen-
etic testing in psychiatry). However, many CNVs associ-
ated with developmental abnormalities (for example, the
22q11.2 deletion) increase risk of mental health prob-
lems across the lifespan. A recent study by van den Bree
and colleagues [138] found that the internet was the
main source of parents’ information about psychiatric
problems associated with 22q11.2 deletion syndrome,
while another study reported that almost half of genetic
counselors were uncomfortable discussing psychiatric
disorders with affected families [139]. This suggests that
there should be greater liaison between pediatricians,
clinical geneticists and psychiatrists in order to appropri-
ately counsel families about these risks and monitor
symptoms.
There is now clear evidence that childhood-onset dis-
orders often persist into adulthood [140,141] and that







Psychosocial environmental risk factors






Severity of early brain insult
Figure 1 Simplified representation of the hypothesized relationship between the number and severity of deleterious genetic
mutations and clinical syndromes. Psychiatric disorders as currently classified are shown as a neurodevelopmental continuum, with intellectual
disability (ID) at one extreme and mood disorders at the other (see [130]). Domains of psychopathology overlap between the clinical syndromes, with
the ultimate clinical phenotype being dependent on both genetic and environmental influences. Positive symptoms refer to abnormal thoughts,
perceptions and behaviour, for example, hallucinations and delusions. Negative symptoms refer to disruption to normal emotions or behaviour, for
example, apathy and lack of emotional reactivity. A gradient of mutational load and cognitive impairment is shown, with ID associated with the
highest mutational load and most severe cognitive impairment, and mood disorders associated with the lowest mutational load/severity and least
impaired cognitive function. The severity of individual syndromes is not represented. Owing to the lack of evidence from adequately powered genetic
studies, attention-deficit/hyperactivity disorder (ADHD) has been omitted from the figure. ASD, autism spectrum disorder; BD, bipolar disorder;
MDD, major depressive disorder; SZ, schizophrenia.
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pairment is a core feature across several disorder cat-
egories [144-147]. Psychiatric secondary care services
are, for the most part, segregated into those that manage
children and adolescents, adults of working age, older
adults and patients with intellectual disability, respect-
ively. Furthermore, neurodevelopmental disorders are
often managed by other services, including clinical gen-
etics, pediatrics and neurology. The evidence from re-
cent genomic studies suggests that the service settings in
which patients with neurodevelopmental disorders find
themselves depend to a large extent on when, and by
whom, they happen to be diagnosed, and that a lifetime
neurodevelopmental perspective should be adopted in
the diagnosis and management of psychiatric disorders
and ID. Effective communication between service pro-
viders is key to providing high-quality care, particularly
during transitions from one service to another.
One of the major barriers to improving the outcome
of patients with severe mental illness is the lack of ef-
fective pharmacological treatments that are well toler-
ated by patients. As a result, psychiatric disorders are
associated with high rates of treatment resistance and
non-compliance due to poor drug efficacy and unaccept-
able side effects. Despite considerable advances in
neuroscience, there have been few if any notable
advances in pharmacotherapy, and as a consequence ofthis and the perceived challenges of the field, many
pharmaceutical companies are discontinuing research in
neuroscience and psychiatry [148]. Recent genetic ad-
vances have identified risk alleles, candidate genes and
molecular pathways that could be exploited in the effort
to identify novel drug targets and psychotherapeutic
agents. However, such developments are going to need
substantial investment in order to translate genetic find-
ings from the laboratory into clinical practice.
In this article, we have emphasized the accumulating
evidence from genetic studies suggesting shared suscep-
tibility across traditional diagnostic categories in psych-
iatry. This implies that at least some of the underlying
biology may not be specific, or at least not at the level of
current diagnoses. However, it is important to recognize
that relatively non-specific risk factors that apply to a
wide variety of cases are easier to identify than those as-
sociated with more specific outcomes. There is evidence
from both family and genomic studies for risk alleles
with differential effects on schizophrenia and bipolar dis-
order [23,149] and also for alleles that have a degree of
specificity to clinical phenotypes that do not necessarily
relate well to traditional diagnostic categories [150]. An-
other example comes from the mounting evidence that
large, rare CNVs that are more prevalent in schizophre-
nia are actually underrepresented in bipolar disorder
[64,65]. Indeed, it seems highly probable that while
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genes and overlapping mechanisms, future research will
identify risk alleles and mechanisms with more specific
effects. The identification of risk alleles with greater
phenotypic specificity will require researchers to tackle
the problem of how to scale up detailed phenotyping to
allow studies of the size required to detect genetic ef-
fects at robust levels of statistical significance. It also
seems likely that we will have to move beyond cross-
sectional descriptions of psychopathology and assemble
data on course and outcome as well as endophenotypes
linked to underlying neurobiological mechanisms. Re-
cent history in psychiatric genetics tells us that these ef-
forts will have to be large scale and collaborative.
Conclusions and future directions
Clinical and epidemiological evidence for the overlap be-
tween psychiatric disorders has been available for some
time. There is now increasing biological evidence for this
overlap. Recent genetic findings suggest that psychiatric
disorders have a complex genetic architecture and sup-
port the existence of a neurodevelopmental gradient of
psychopathology and associated cognitive impairment.
These findings highlight the need to improve current
diagnostic systems and to develop better treatments tar-
geted at underlying biology. Future research studying
networks rather than individual genes and proteins, and
relating network abnormalities to behavioral, neuroimag-
ing and clinical phenotypes will be key to achieving
these aims. However, the complexity of psychiatric phe-
notypes and the relative inaccessibility of the human
brain pose considerable challenges to both basic and
clinical neuroscientific research. It seems likely that
there will need to be a focus on large-scale experiments,
requiring interdisciplinary and international collabor-
ation, if we are to make significant progress.
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